Inducible sustained ventricular tachycardia refractory to individual class I drugs: Effect of adding a second class I drug

Duffy, C.Elise; Swiryn, Steven; Bauernfeind, Robert A.; Strasberg, Boris; Palileo, Edwin; Rosen, Kenneth M.

doi:10.1016/0002-8703(83)90685-3

Cited by 17 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coadministration of procainamide with quinidine (Kim et al, 1985), and propafenone with procainamide or quinidine (Klein et al, 1987) increased the suppression of premature ventricu1ar complexes and/or ventricu1ar tachycardias compared to effects with monotherapy. However, Duffy et al (1983) did not find any additional benefits with the coadministration of procainamide wi th quinidine or disopyramide agains t ventricular tachycardias.…”

Section: Action Potential Durationmentioning

confidence: 76%

Electrophysiological interactions between disopyramide and its major metabolite, mono-N-dealkyldisopyramide, in canine ventricular tissue

Toy

Sasyniuk

1990

European Journal of Pharmacology

View full text Add to dashboard Cite

Section: Action Potential Durationmentioning

confidence: 76%

Electrophysiological interactions between disopyramide and its major metabolite, mono-N-dealkyldisopyramide, in canine ventricular tissue

Toy

Sasyniuk

1990

European Journal of Pharmacology

View full text Add to dashboard Cite

Worsening of Ventricular Tachycardia by Amiodarone

Gallastegui¹,

Bauman²,

Anderson³

et al. 1988

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The details of worsening of ventricular tachycardia in 8 (4.1%) of 194 patients receiving treatment with amiodarone are reported. Two forms of amiodarone-induced tachycardia were recognized: first, the development of new tachycardias (three patients) and second, a change in the pattern of recurrence of clinical tachycardia (five patients). In retrospect, the time from the initiation of amiodarone to the initial documentation of worsening ranged from 1 to 23 days (mean +/- SD, 9.4 +/- 8.2 days) and the time from the initiation of therapy to the recognition of worsening ranged from 6 to 26 days (14.6 +/- 10.1 days). Seven patients survived the worsening of tachycardia and one died. The total dose of amiodarone received and the duration of administration did not correlate with time to manifestation or time to resolution of worsening. This report emphasizes that worsening of ventricular tachycardia as a result of amiodarone is often difficult to differentiate from inadequate drug loading or early recurrence of 2 patient's clinical tachycardia. Further, because of the pharmacokinetics of the drug, the manifestations of worsening may be prolonged. In the cases reported, it ranged from 2 to 26 days (7.9 +/- 8.3 days), which is longer than previously reported. Because of the potential for amiodarone to cause life-threatening worsening of ventricular tachycardia and in accordance with current results, a period of in-hospital monitoring of at least 10 days at the start of therapy with amiodarone is recommended.

show abstract

Antiarrhythmic Drug Therapy for Patients with Ventricular Tachyarrhythmias in the Setting of Left Ventricular Dysfunction: 1. The Role of Propafenone 2. The Role of Adjunct Beta-Blockade

Brodsky

Allen

Luckett

et al. 1987

Developments in Cardiovascular Medicine

View full text Add to dashboard Cite

Inducible sustained ventricular tachycardia refractory to individual class I drugs: Effect of adding a second class I drug

Cited by 17 publications

References 40 publications

Electrophysiological interactions between disopyramide and its major metabolite, mono-N-dealkyldisopyramide, in canine ventricular tissue

Electrophysiological interactions between disopyramide and its major metabolite, mono-N-dealkyldisopyramide, in canine ventricular tissue

Worsening of Ventricular Tachycardia by Amiodarone

Antiarrhythmic Drug Therapy for Patients with Ventricular Tachyarrhythmias in the Setting of Left Ventricular Dysfunction: 1. The Role of Propafenone 2. The Role of Adjunct Beta-Blockade

Contact Info

Product

Resources

About